About

Penetration of anti-cancer agents into and throughout solid tumours is widely recognised as presenting a major limitation to their effectiveness. OxSonics^®Therapeutics’ proprietary platform technology, SonoTran^®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.

The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.

The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.

OxSonics is based in Oxford in the UK.

Vision

As a global leader in ultrasound-based drug delivery, OxSonics’ vision is to maximise the potential of existing and emerging cancer therapies for the benefit of cancer patients world-wide. OxSonics Therapeutics proprietary platform, SonoTran, has been designed by clinicians for clinicians.

Imagine a technology that:

increased efficacy and/or reduced toxicity

was drug agnostic and didn’t require any drug reformulation

was safe and easy to use

seamlessly integrated into current clinical workflows

was cost effective

Team

All 14 /Board 5 /Clinical Advisors 3 /Management 8

Dr Colin Story

Chief Executive Officer, Executive Director & Co-Founder

Prof. Constantin Coussios FREng

Chief Scientific Officer, Non-Executive Director & Co-Founder

Dr Christian Coviello

Engineering Director & Co-Founder

Mr Chris Hill

Finance Director

Dr Cliff Rowe

Associate Director, Development

Dr Dinah Parker

Associate Director, Clinical & Regulatory Affairs

Dr Ruth Barrett

Associate Director, Operations

Prof. Robert Carlisle

Oncology Director & Co-Founder

Dr Matthew Frohn

Non-Executive Director

Mr Glyn Edwards MBE

Non-Executive Director

Mr George Robinson

Board Member

Prof. Fergus Gleeson PhD FRCP FRCR

Clinical Advisor

Prof. Hardev Pandha PhD FRACP FRCP CSST

Clinical Advisor

Mr Robert Jones PhD FRCS

Clinical Advisor

History

OxSonics was founded in 2013 to commercialise ground-breaking technological advances developed over more than ten years at the Biomedical Ultrasonics, Biotherapy and Biopharmaceuticals Laboratory (BUBBL) at the University of Oxford in the UK. BUBBL is an internationally-recognized centre of excellence in therapeutic ultrasound and drug delivery within the Oxford Institute of Biomedical Engineering.

By working closely with both medical oncologists and oncology radiologists, OxSonics is developing the SonoTran platform in order to provide for the needs of patients and clinicians alike but also to comply with applicable regulatory standards.

In conjunction with advancing its manufacturing capabilities, OxSonics has also generated compelling pre-clinical data across several drug classes and cancer types.

Intellectual Property

OxSonics’ proprietary intellectual property portfolio consists of multiple patent families and a substantial body of know-how that collectively provide protection to several key elements of the SonoTran system. Patents protecting OxSonics core technology have been granted across key jurisdictions with several further patents at an advanced stage of prosecution.